Jupiter Life Line Hospitals Limited
JLHL.BO
Bombay Stock Exchange1,447.80
INR
-14.45
- -
Jupiter Life Line Hospitals Limited
JLHL.BO
(Bombay Stock Exchange)
Recent
price
1,447.80
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Jupiter Life Line Hospitals Limited operates as a multi-specialty tertiary and quaternary healthcare provider focused on Western India, delivering comprehensive patient care across three operational hospitals in Thane, Pune, and Indore with a total bed capacity of 1,194 beds, including 377 in Thane, 353 in Pune, and 375 in Indore; the company offers over 30 key specialties such as cardiology, oncology, orthopaedics, neurology and neurosciences, paediatrics, organ transplant, haematology, surgical gastroenterology, bariatric surgery, breast care, chest medicine, dental care, and precision-based quaternary services including brachytherapy, radiotherapy, robotic surgery, robotic knee replacement, robotic neurorehabilitation, stereotactic linear accelerators, multi-slice PET/CT, 3 Tesla MRI, 128-slice CT scanners, catheterisation labs, gait labs, and endoscopic ultrasound. Founded in 2007 and headquartered in Mumbai, Maharashtra, with its flagship facility on Eastern Express Highway in Thane West, the company serves urban and underserved micro-markets in the Mumbai Metropolitan Region and surrounding areas through an all-hub-no-spoke model, emphasizing advanced infrastructure like 1,000 sq ft per bed, NABH and NABL accreditations, positive/negative pressure isolation rooms, high-efficiency particulate air filters, and Asia's finest neurorehabilitation centers in Thane and Indore. Jupiter targets self-pay patients, insurance companies, and government schemes, with a diversified payor mix where self-payers constitute around 45-50%, insurance and others about 48-50%, and government schemes 1-2%, while maintaining average revenue per occupied bed ranging from Rs 40,904 in Indore to Rs 61,920 in Thane, average occupancy of 54-72%, and average length of stay of 3.93-4.50 days. In recent developments, the company completed its initial public offering in FY2023-24, achieving a debt-free status with net cash reserves of approximately Rs 300 crore, repaying prior obligations and enabling expansion funding through internal accruals; it acquired 8,433 square meters of land in Ghodbunder-Mira Road, Thane district, for Rs 400 crore to develop a 300-bed greenfield multispecialty hospital targeting underserved areas like Dahisar, Mira Bhayandar, and Vasai Virar, with completion planned over four years. Further expansions include construction of a 500-bed hospital in Dombivli, Maharashtra, commenced in April 2023 with Rs 120-125 crore initial investment plus Rs 200-250 crore in phase one; a 500-bed facility in Bibwewadi, South Pune; additional 75 beds via two floors in Indore raising capacity above 300 beds; 22 beds in Baner, Pune; and a second Pune hospital, aiming to more than double total capacity to 2,500 beds over the next four years with Rs 300 crore capital expenditure annually in FY2025 and FY2026 excluding the Thane project, while reporting strong financials like 20.5% YoY H1FY25 revenue growth to Rs 612.8 crore and 52.91% Q2FY25 net profit rise to Rs 51.50 crore. The National Company Law Tribunal approved the amalgamation with subsidiary Medulla on September 9, 2025, streamlining operations amid ongoing projects like Dombivli targeting Q1 next fiscal year operationalization.